Emergent Biosolutions

J.P. Morgan is out with its report today on Emergent BioSolutions (NYSE: EBS), raising its PT from $27 to $35. In a note to clients, J.P. Morgan writes, "We are updating our estimates, raising our Dec 11 PT (to $35 from $27), and reiterating our OW rating on EBS following today's news that the US...

JP Morgan has raised the price target on Emergent BioSolutions (NYSE: EBS) from $27 to $35 and maintains its Overweight rating.

In a report published by J.P. Morgan, Emergent BioSolutions (NYSE: EBS) reported 4Q10 results that were relatively uneventful seeing that the company announced preliminary results and 2011 guidance at the J.P. Morgan conference in January. J.P. Morgan said that it remains optimistic on Emergent's...

James Altucher has taken an interesting look at Pharmathene, Inc. (AMEX: PIP), a company he believes can go from its current price, $2.64, to $20 or higher. There are two reasons for his prediction. The first relates to a lawsuit against SIGA Technologies, Inc. (NASDAQ: SIGA), a company that was...